PDCD1 and melanoma: Furthermore, a retrospective real-life cohort analysis of 1016 Massachusetts General Hospital patients who received immunotherapy, mostly anti-PD1, for a variety of malignancies (primarily melanoma) revealed a 17% incidence of AKI, with 3% probably attributed to immunological causes.